Literature DB >> 10705263

Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis.

B Schaaf1, A Wieghorst, S P Aries, K Dalhoff, J Braun.   

Abstract

BACKGROUND: Pulmonary inflammation in bronchiectasis, pneumonia and idiopathic pulmonary fibrosis (IPF) is dominated by neutrophils. Pathophysiologic differences are seen in the degree of airway and tissue destruction. Neutrophil activation and neutrophil proteolytic activity might differ between bronchiectasis, pneumonia and IPF.
OBJECTIVE: The aim of this study was to determine whether levels of inflammatory and protective markers in bronchoalveolar lavage (BAL) differed among cases of bronchiectasis, pneumonia and IPF.
METHODS: We studied 11 bronchiectasis patients (group 1), 30 pneumonia patients (group 2), 15 IPF patients (group 3) and 12 healthy volunteers (group 4). In the bronchoalveolar lavage fluid, concentrations of alpha(1)-proteinase inhibitor, myeloperoxidase (MPO) and elastase-alpha(1)PI complex were determined using immunoluminometric assays. Elastase inhibition capacity (EIC) and elastase activity were determined using a colorimetric assay.
RESULTS: No EIC, but free elastase activity, was found in 82% of group 1, 20% of group 2, 20% of group 3 and 0% of group 4. Median MPO concentration was highest in group 1: 7,951 ng/ml (16th-84th percentile [16-84%]: 256-36,342) vs. 692 ng/ml (106-2,279; group 2), 332 ng/ml (98-1,657; group 3), and 0.12 ng/ml (0.08-0.26; group 4). Bronchiectasis patients with bronchial Pseudomonas infection showed higher amounts of neutrophils (p < 0.01) and higher elastase activity (p < 0.05) than patients with sterile lavage.
CONCLUSION: Bronchiectasis patients show a severe imbalance between neutrophil activity and protective molecules leading to possible lung destruction. Chronic Pseudomonas infection might trigger neutrophil activation. Future research and treatment strategies should focus on increased bacterial clearance and inhibition of neutrophil toxicity. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705263     DOI: 10.1159/000029463

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  19 in total

1.  Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias.

Authors:  N Yoshimi; Y Ikura; Y Sugama; S Kayo; M Ohsawa; S Yamamoto; Y Inoue; K Hirata; H Itabe; J Yoshikawa; M Ueda
Journal:  Lung       Date:  2005 Mar-Apr       Impact factor: 2.584

Review 2.  Infectious disease, the innate immune response, and fibrosis.

Authors:  Alessia Meneghin; Cory M Hogaboam
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Authors:  Charlie Strange; Robert M Senior; Frank Sciurba; Scott O'Neal; Alison Morris; Stephen R Wisniewski; Russell Bowler; Harry S Hochheiser; Michael J Becich; Yingze Zhang; Joseph K Leader; Barbara A Methé; Naftali Kaminski; Robert A Sandhaus
Journal:  Ann Am Thorac Soc       Date:  2015-10

4.  Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa.

Authors:  Avinash Sonawane; Jeevan Jyot; Russell During; Reuben Ramphal
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 5.  Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Authors:  Aleksandra Nikolic
Journal:  Lung       Date:  2018-05-12       Impact factor: 2.584

6.  Neutrophil elastase gene polymorphisms: modulators of response to therapy in childhood bronchiectasis?

Authors:  Aleksandra Nikolic; Katarina Milosevic; Srdjan Boskovic; Branimir Nestorovic
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

7.  Overexpression of alpha1-protease inhibitor and galectin-1 in radiation-induced early phase of pulmonary fibrosis.

Authors:  Hee-Soon Im; Hyung-Doo Kim; Jie-Young Song; Youngsoo Han; Do-Youn Lee; Chan-Wha Kim; Yeon-Sook Yun
Journal:  Cancer Res Treat       Date:  2006-04-30       Impact factor: 4.679

Review 8.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

9.  The periplasmic serine protease inhibitor ecotin protects bacteria against neutrophil elastase.

Authors:  Christopher T Eggers; Iain A Murray; Valerie A Delmar; Anthony G Day; Charles S Craik
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

10.  Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency.

Authors:  Derek W Russell; Amit Gaggar; George M Solomon
Journal:  Ann Am Thorac Soc       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.